Alaunos faces Nasdaq delisting threat over failure to meet $2.5 million stockholders’ equity rule

TCRT•2026-10-09

Alaunos Therapeutics received a Nasdaq delisting notice on Oct. 5, 2026, for failing to meet the $2.5 million stockholders’ equity requirement.

1. Nasdaq listing notice

Alaunos Therapeutics said it plans to request a Nasdaq hearings panel review, which would pause any suspension or delisting at least until the hearing. The company is evaluating strategic alternatives with a financial adviser to bolster its financial position and regain compliance.

Sources

Alaunos faces Nasdaq delisting threat over failure to meet $2.5 million stockholders’ equity rule

Sec

Alaunos faces Nasdaq delisting threat over failure to meet $2.5 million stockholders’ equity rule

1. Nasdaq listing notice

Related News

Wheels Up amends Adjusted EBITDA, EBITDAR reconciliations under updated definition in 8-K/A

LB Pharmaceuticals grants 200,000-share option awards to new CMO and CFO

Volato Group signs $1 billion equity line of credit with DFU LLC

Sources

Alaunos faces Nasdaq delisting threat over failure to meet $2.5 million stockholders’ equity rule

Sound Point Meridian Capital estimates Sept. 30 NAV per share at $9.04-$9.14

Vinci Compass to report Q3 2026 results after market close, host conference call